Download PDF
Thromb Haemost 2014; 111(01): 8-9
DOI: 10.1160/TH13-10-0846
Invited Editorial Focus
Schattauer GmbH

The elusive disconnection between mortality and early stent thrombosis: Observations from the CHAMPION-PHOENIX trial

Freek W. A. Verheugt
1   Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, Netherlands
› Author Affiliations
Further Information

Publication History

Received: 28 October 2013

Accepted after major revision: 28 October 2013

Publication Date:
21 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Van Werkum JW, Heestermans AA, De Korte FI. et al. Long-term clinical outcome after a first angio-graphically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation 2009; 119: 828-824.
    CrossrefPubMedGoogle Scholar
  • 2 Wiviott SD, Braunwald E, McCabe CH. et al. Pra- sugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
    CrossrefPubMedGoogle Scholar
  • 3 Wallentin L, Becker RC, Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
    CrossrefPubMedGoogle Scholar
  • 4 Steg PG, James SK, Atar D. et al. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569-2619.
    CrossrefPubMedGoogle Scholar
  • 5 Gibson CM, Aradi D, Komócsi A. et al. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thromb Haemost 2013; 109: 93-101.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Gibson MC, Chakrabarti AK, Mega J. et al. Reduction of stent thrombosis in patients with acute coronary syndrome treated with rivaroxaban in ATLAS ACS 2-TIMI 51. J Am Coll Cardiol 2013; 62: 286-290.
    CrossrefPubMedGoogle Scholar
  • 7 Alexopoulos D, Xanthopoulou I, Gkizas V. et al. Randomized assessment of ticagrelor versus pra-sugrel antiplatelet effects in patients with ST-seg-ment-elevation myocardial infarction. Circ Car-diovasc Interv 2012; 5: 797-804.
    CrossrefPubMedGoogle Scholar
  • 8 Parodi G, Valenti R, Bellandi B. et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61: 1601-1606.
    CrossrefPubMedGoogle Scholar
  • 9 Serebruany VL. Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel. Thromb Hae-most 2012; 108: 1024-1027.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Serebruany VL, Atar D. Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?. Thromb Haemost 2012; 108: 412-414.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Ohman EM, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Thromb Haemost 2011; 105: 763-765.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Wallentin L, Becker RC, James SK. et al. The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Thromb Haemost 2011; 105: 760-762.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Serebruany VL. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105: 752-759.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Verheugt FWA. Outcomes of positive randomized controlled clinical trials: double-blind or double vision?. Thrombos Haemost 2012; 108: 410-411.
    PubMedGoogle Scholar
  • 15 Steg PG, Bhatt DL, Hamm CW. et al. Effect of can-grelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013 Epub ahead of print.
    PubMedGoogle Scholar
  • 16 Serebruany VL, Pokov AN, Fortmann SD. et al. Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge. Thromb Haemost 2014; 111: 03-07.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Bhatt DL, Stone GW, Mahaffey KW. et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368: 1303-1313.
    CrossrefPubMedGoogle Scholar
  • 18 Bhatt DL, Lincoff AM, Gibson CM. et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-2341.
    CrossrefPubMedGoogle Scholar
  • 19 Harrington RA, Stone GW, McNulty S. et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-2329.
    CrossrefPubMedGoogle Scholar
  • 20 CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930-942.
    CrossrefPubMedGoogle Scholar
  • 21 Spencer FA, Moscucci M, Granger CB. et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?. Circulation 2007; 116: 2793-2801.
    CrossrefPubMedGoogle Scholar